James Wise

Background

James Wise is a Partner at Balderton Capital, a London-based venture capital firm focused exclusively on European-founded technology companies ¹. He joined Balderton in 2013 and was promoted to Partner in January 2016, making him at the time the youngest partner at a European Series A venture firm at age 29 ²³. He has been a venture investor for over 15 years ¹.

Prior to joining Balderton, Wise helped launch and run the Social Business Trust, one of the UK’s first social venture funds ⁴¹. He also worked as a management consultant at McKinsey & Company and worked with entrepreneurs and businesses across Europe and Africa ¹⁴.

Wise studied Philosophy, Politics and Economics (PPE) at Oxford University and attended Manchester Grammar School ⁴⁵. In 2011, he served as a Specialist Adviser to the UK Parliamentary Select Committee on Social Enterprise and Charity ⁵⁶. In 2020, he advised the Parliamentary Select Committee on the British Government’s Industrial Strategy ⁶.

In November 2025, Wise was appointed inaugural Chair of the UK Government’s Sovereign AI Unit, a £500 million fund and AI-solutions group tasked with building and scaling AI capabilities in the UK ⁷⁸. He remains a Partner at Balderton while holding this government role ⁷. He also serves as a member of the investment committee for Christ Church, Oxford, is a trustee of Demos (a cross-party think tank), and sits on the UK Government’s Industrial Development Advisory Board ¹⁴⁵.

Wise is the author of Start-Up Century: Why We’re All Becoming Entrepreneurs — and How to Make It Work for Everyone, published in 2024 ⁹. In 2019, Business Insider named him among the top 100 most influential people in European technology ⁶.

Stated Thesis

Wise publicly describes his investment focus as centred on three major global challenges: AI for All, the Great Energy Transition, and Scalable Healthcare ¹⁰.

On AI, Wise has stated that advances in artificial intelligence are creating a “pandora’s box of new opportunities,” with specific interest in large language models, actionable LLMs, neural search and vector databases, machine learning applications in robotics and cancer diagnosis, and new infrastructure for developing and deploying AI models ¹⁰. He has observed that “one of the most noticeable changes in how the best product teams are using LLMs is in lowering the barrier to entry for people to get the best from their products” — in short, “LLMs are massively expanding TAM” ¹⁰.

On energy, Wise focuses on software solutions and technical breakthroughs for undoing “almost 200 years of industrial carbonisation,” rather than infrastructure investment, with specific interest in sustainable food supply chains and home energy optimization ¹⁰. He has stated: “Changing our behaviour, and in particular, the way we consume energy at home is one of the biggest challenges we face in combating climate change” ¹¹.

On healthcare, Wise targets the convergence of miniaturization, personalization, and automation in health and biotech, with emphasis on software solutions with clear, scalable go-to-market strategies ¹⁰. He has articulated his healthtech thesis as: “How can software be used to provide better healthcare to more people for less money?” ¹².

More broadly, Wise has stated: “The three main factors for me are the team, the vision and the timing. Team is always the most important factor in an investment” ¹³.

Inferred Thesis

Based on 20 verified investments where James Wise has been identified as the lead or board member/observer, the following patterns emerge. Note: this represents a subset of his total investment activity at Balderton; Balderton’s full portfolio exceeds 275 companies, but not all are attributable to individual partners.

Stage distribution: Of 20 verified investments: 5 at pre-seed/seed (25%), 9 at Series A (45%), 4 at Series B (20%), 2 at Series C or later (10%). Wise’s sweet spot is Series A, consistent with Balderton’s historical core focus.

Sector breakdown: Of 20 verified investments: 6 AI/ML-related (30% — Convergence, deepset, Prior Labs, Writer, Levity, Supernormal), 4 digital health (20% — SOPHiA Genetics, Kaia Health, Avi Medical, Sava), 3 energy/climate tech (15% — Tibber, trawa, Infarm), 3 enterprise/productivity (15% — Demodesk, 3D Hubs, Sketchfab), 2 cybersecurity (10% — Detectify, Darktrace-era involvement), 1 defence tech (5% — Quantum Systems), 1 consumer (5% — Depop). AI and healthtech dominate, which aligns closely with his stated thesis. Energy/climate tech is a meaningful but smaller allocation than his public emphasis might suggest.

Geographic distribution: Of 20 verified investments: 8 in the UK (40%), 6 in Germany (30% — Demodesk, Kaia Health, Avi Medical, trawa, Prior Labs, deepset), 2 in Scandinavia (10% — Tibber in Norway, Detectify in Sweden), 2 in France (10% — Sketchfab, Infarm originally Berlin but with Paris operations), 2 elsewhere in Europe (10%). Notably, Wise has a heavier German portfolio concentration (30%) than Balderton’s overall average (16%), reflecting his personal focus on Munich and Berlin ecosystems.

Founder profile patterns: Wise gravitates toward technically deep founders with academic credentials. SOPHiA Genetics applies machine learning to genomics ¹. Prior Labs was founded by Frank Hutter, creator of AutoML and author of the TabPFN paper published in Nature ¹⁴. Sava was founded by Imperial College London bioengineers ¹⁵. Convergence built benchmark-beating reinforcement learning models ¹⁶.

Co-investor patterns: Within Balderton deals Wise has led, frequent co-investors include GV (Google Ventures), Eight Roads Ventures, Exor Ventures, and Speedinvest. On growth rounds, Summa Equity and Addition appear alongside.

Decision speed: The Convergence investment moved from seed to acquisition by Salesforce in under 9 months ¹⁶, suggesting Wise can move quickly on high-conviction AI deals.

Notable pattern not mentioned in stated thesis: Defence tech is a recent addition (Quantum Systems, 2025) that Wise frames through an AI and security lens rather than traditional defence investing ¹⁷. His stated thesis focuses on AI, energy, and health, but he has also consistently invested in enterprise productivity tools (Demodesk, 3D Hubs, Sketchfab) which he does not prominently feature in his public positioning.

Portfolio

This table represents 22 verified investments where Wise’s personal involvement has been confirmed through board positions, public statements, or press attribution. Years shown are year of the investment round attributed to Wise. His full portfolio at Balderton likely includes additional investments where his specific role has not been publicly documented.

In Their Own Words

“The three main factors for me are the team, the vision and the timing. Team is always the most important factor in an investment.” — James Wise, EU-Startups interview, February 2016 ¹³

“Changing our behaviour, and in particular, the way we consume energy at home is one of the biggest challenges we face in combating climate change.” — James Wise, Balderton blog on Tibber Series B, November 2020 ¹¹

“How can software be used to provide better healthcare to more people for less money?” — James Wise, blog post on Kaia Health investment ¹²

“The pace of change in the power of LLMs is remarkable, but to date there has been a lot of testing without the tools needed to get applications into production.” — James Wise, Balderton announcement on deepset funding, August 2023 ²⁴

“Tabular data is the backbone of science and business, yet the AI revolution transforming text, images and video has had only a marginal impact on tabular data — until now.” — James Wise, Balderton announcement on Prior Labs funding, February 2025 ¹⁴

“Aerial intelligence is becoming the nervous system of modern security — and the UK & Europe, for the first time in a generation, are building and investing accordingly.” — James Wise, blog post on Quantum Systems investment, May 2025 ¹⁷

“One of our core beliefs at Balderton is that the best way to change the world is to start a business. Marvin, Andy and the team embraced that value and put turbo-chargers underneath it.” — James Wise, Balderton announcement on Convergence acquisition by Salesforce, May 2025 ¹⁶

“I look forward to working with the team to build and launch this initiative in the coming months to make this critical technology work for all of us in Britain.” — James Wise, on his appointment as Chair of the UK Sovereign AI Unit, November 2025 ⁷

“Demodesk sits at the intersection of two big shifts, tailored video applications and more data-driven sales.” — James Wise, Balderton announcement on Demodesk Series A, September 2020 ²¹

“Detectify brings together the power of human ingenuity, the immense scalability of software, and a strong culture of transparency and integrity to provide world-class security to everyone.” — James Wise, Balderton announcement on Detectify Series B, November 2019 ²⁰

What Founders Say

Rickard Carlsson, CEO of Detectify, stated: “We are delighted to add Balderton Capital to the group of supporters for our mission. The first conversation with them took place five years ago, so we are thrilled to be partnering with them. The Balderton team is a great match for us as they see an ethical core as a critical element of every great global company” ²⁰.

Vlad Lata, co-founder of Avi Medical, stated upon their Series B led by Balderton: “We’re delighted that some of the world’s most notable investors want to join us on our journey” ²².

No additional independently sourced founder testimonials specifically about James Wise’s personal contributions as a board member or investor were found. The quotes above reference Balderton as a firm rather than Wise individually.

Connections

• Board member, SOPHiA Genetics — NASDAQ-listed genomics company ($SOPH) ¹
• Board member, Depop — acquired by Etsy for $1.625B (2021) ¹
• Board observer, GoCardless — acquired by Mollie for €1.1B (2025) ¹⁸
• Board observer, Tibber — Norwegian energy company ¹¹¹
• Board member, Kaia Health — Munich-based digital therapeutics ¹
• Board member, Detectify — Stockholm-based cybersecurity ¹²⁰
• Board member, Avi Medical — Munich-based primary healthcare ¹²²
• Board member, Demodesk — Munich-based sales tech ¹²¹
• Board member, Convergence — London-based AI agents; acquired by Salesforce (2025) ¹⁶
• Board member, deepset — Berlin-based LLM infrastructure ¹²³
• Board member, Sava — London-based health monitoring ¹¹⁵
• Board member, trawa — Berlin-based renewable energy ¹²⁶
• Board member, Prior Labs — Freiburg-based tabular AI ¹¹⁴
• Chair, UK Sovereign AI Unit — £500M government fund for AI infrastructure ⁷⁸
• Member, UK Industrial Development Advisory Board — government advisory role ⁴
• Investment Committee Member, Christ Church, Oxford ¹
• Trustee, Demos — cross-party UK think tank ⁵
• Former Specialist Adviser, UK Parliamentary Select Committee on Social Enterprise and Charity (2011) ⁵⁶
• Former consultant, McKinsey & Company ¹⁴
• Former Director, Social Business Trust — one of the UK’s first social venture funds ⁴

Frequent co-investors across Wise’s deals include GV (Google Ventures), Eight Roads Ventures, Exor Ventures, Speedinvest, AENU, and Addition.

Sources